PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Decrease in Short Interest

PolyPid Ltd. (NASDAQ:PYPD) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 4,600 shares, a decline of 14.8% from the May 31st total of 5,400 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 3,400 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of PolyPid in a report on Tuesday, June 18th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. purchased a new position in shares of PolyPid Ltd. (NASDAQ:PYPD) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid comprises approximately 1.8% of Rosalind Advisors Inc.’s holdings, making the stock its 20th biggest holding. Rosalind Advisors Inc. owned about 8.67% of PolyPid as of its most recent SEC filing. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Price Performance

Shares of PYPD stock opened at $4.24 on Tuesday. PolyPid has a 12 month low of $3.57 and a 12 month high of $12.30. The stock has a 50 day moving average of $4.44 and a 200-day moving average of $5.12. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.60.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.96) by $0.59. Research analysts predict that PolyPid will post -4.98 EPS for the current year.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.